ACHE and myasthenia gravis: Firstly, one of the prototypes of AChE inhibitor, pyridostigmine, has been reported with moderate pharmacological activity (AChE reversible inhibition activity IC50 = 40 μM; being of close IC50 to marrubiin), yet being marketed and FDA-approved for management of myasthenia gravis owing to its clinical efficient in controlling the reversing muscle weakness while possessing safe profile (Cleveland Clinic; https://my.clevelandclinic.org/health/drugs/18042-pyridostigmine-tablets-regular-release).